glycopyrrolate has been researched along with carbostyril in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 103 (81.75) | 24.3611 |
| 2020's | 23 (18.25) | 2.80 |
| Authors | Studies |
|---|---|
| Buhl, R; Dolker, M; Jones, F; Laforce, C; Martin, C; Overend, T; van Noord, JA | 1 |
| Dolker, M; Fabbri, LM; Horton, R; Martin, C; Overend, T; Van de Maele, B | 1 |
| Banerji, D; Barnes, N; Bateman, ED; Ferguson, GT; Gallagher, N; Green, Y; Henley, M | 1 |
| Alagappan, VK; Banerji, D; Chapman, KR; Chen, H; Dahl, R; Kho, P; Mehta, R; Rudolf, M | 1 |
| Schachter, EN | 1 |
| Thompson, H | 1 |
| Baldwin, M; Buckley, F; Capkun-Niggli, G; Cope, S; Donohue, JF; Ellis, A; Jansen, JP; Jones, P; Kraemer, M | 1 |
| Alagappan, VK; Banerji, D; Chen, H; Dahl, R; Jadayel, D | 1 |
| Alagappan, VK; Banerji, D; Chen, H; D'Urzo, A; Decramer, M; Gallagher, N; Kulich, K; Mahler, DA; White, T; Worth, H | 1 |
| Antoniu, S; Râjnoveanu, RM; Ulmeanu, R | 1 |
| Chanez, P; Roche, N | 1 |
| Tashkin, DP | 1 |
| Alagappan, VK; Banerji, D; Bateman, ED; Chen, H; D'Andrea, P; Pallante, J; Vogelmeier, CF | 1 |
| Han, MK | 1 |
| Arrasate, C; Banerji, D; Chen, H; D'Andrea, P; Decramer, M; Ficker, JH; Niewoehner, DE; Sandström, T; Taylor, AF; Wedzicha, JA | 2 |
| Yaqub, F | 1 |
| Van Meerhaeghe, A; Vanhaeverbeek, M | 1 |
| Banerji, D; Beeh, KM; Beier, J; D'Andrea, P; Henley, M; Jadayel, D; Korn, S | 1 |
| Plaza, V; Rodrigo, GJ | 1 |
| Brown, M; Drollmann, A; Febbraro, S; Hara, H; Jones, I; Perry, S; Sechaud, R | 1 |
| Aumann, J; Chen, H; Goyal, P; Henley, M; McBryan, D; Vincken, W | 1 |
| Frampton, JE | 1 |
| Lipworth, BJ | 1 |
| Bateman, E | 1 |
| Ulrik, CS | 2 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Banerji, D; Buhl, R; Chen, H; D'Andrea, P; Dahl, R; Fogel, R; Schubert-Tennigkeit, A; Wedzicha, JA | 1 |
| Calzetta, L; Cazzola, M; Facciolo, F; Matera, MG; Rogliani, P; Segreti, A | 1 |
| Asukai, Y; Costa-Scharplatz, M; Dimova, M; Keininger, D; Mezzi, K; Price, D; Ställberg, B | 1 |
| Cazzola, M; Matera, MG; Rogliani, P | 2 |
| Maselli, R; Matera, MG; Pelaia, G | 1 |
| Clark, AR; Colthorpe, P; Haynes, A; Khindri, SK; Machineni, S; Perry, SA; Rao, N; Ung, K; Weers, JG | 1 |
| Babu, KS; Morjaria, JB; Prakash, A | 1 |
| Buhl, R; Foerster, K; Gessner, C; Hiltl, S; Korn, S; Schuermann, W; Sieder, C | 1 |
| Baroni, M; Incorvaia, C; Montagni, M; Riario-Sforza, GG; Ridolo, E | 1 |
| Kozielski, J | 1 |
| Horita, N; Kaneko, T | 1 |
| Banerji, D; Humphries, M; Patalano, F; Thach, C; Wang, C; Wang, L; Zhang, N; Zhong, N; Zhou, X | 1 |
| Ayers, T; Banerji, D; FowlerTaylor, A; Kerwin, E; Lloyd, M; Mahler, DA; Maitra, S; Patalano, F; Thach, C | 1 |
| Cazzola, M; Poletti, V; Rossi, A; Zanardi, E | 1 |
| Hubert, M | 2 |
| Cockle, SM; Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Donohue, JF | 2 |
| Abdel Ghany, MF; Hussein, LA; Magdy, N; Yamani, HZ | 1 |
| Einecke, D | 3 |
| Bartels, C; Bieth, B; Demin, I; Gautier, A; Graham, G; Sechaud, R; Tillmann, HC | 1 |
| Anzueto, A; Halpin, DM; Metzdorf, N; Pieper, MP; Richard, F; Vogelmeier, C | 1 |
| Ayers, RT; Banerji, D; Chapman, KR; Fogel, R; Patalano, F; Roche, N; Thach, C; Vestbo, J; Vogelmeier, CF; Wedzicha, JA | 1 |
| Banerjee, R; D'Andrea, P; Eckert, JH; Gifford, AH; Jessop, N; Mahler, DA; Mota, F; Satti, A | 1 |
| Kuwahira, I | 1 |
| Calzetta, L; Cazzola, M; Facciolo, F; Matera, MG; Ora, J; Puxeddu, E; Rogliani, P | 1 |
| Baier, M; Kirsten, A; Mailänder, C; Watz, H | 1 |
| Fernández-Villar, A; Leiro-Fernández, V; Priegue Carrera, A | 1 |
| Carrasco, J; Chehab, S; Gruenberger, JB; Keininger, DL; Molimard, M; Pitotti, C; Price, D; Reza Maleki-Yazdi, M; Sauvage, E | 1 |
| Banerji, D; Vogelmeier, CF; Wedzicha, JA | 1 |
| Suissa, S | 1 |
| Contoli, M; Morelli, P; Papi, A | 1 |
| Franssen, FM; Vanfleteren, LE; Wouters, EF | 1 |
| Ito, YM; Kanda, R; Konno, S; Makita, H; Nakano, Y; Nishimura, M; Ogawa, E; Seto, R; Shimizu, K; Suzuki, M | 1 |
| Bader, G; Banerji, D; Fogel, R; Humphries, MJ; Mezzi, K; Patalano, F; Vogelmeier, C; Zhong, N | 1 |
| Azzola, A; Brutsche, M; Clemens, A; Domenighetti, G; Fitting, JW; Frey, JG; Geiser, T; Kostikas, K; Salomon, J; Schmidt, U; Sigrist, T; Stolz, D; Turk, AJ; Wild, C | 1 |
| Hwang, YI; Jung, JY; Jung, KS; Kim, S; Kim, TH; Lee, JH; Lee, SW; Park, HY; Park, JW; Rhee, CK | 1 |
| Kadoya, K; Kaga, N; Liu, X; Nagahama, KY; Namba, Y; Orimo, A; Taka, H; Takahashi, K; Togo, S; Tulafu, M | 1 |
| Corhay, JL | 1 |
| Ficker, JH; Rabe, KF; Welte, T | 1 |
| Banerji, D; Fogel, R; Fucile, S; Kostikas, K; Mezzi, K; Shen, S; Tsiligianni, I | 1 |
| Aalamian-Mattheis, M; Castellani, W; Clemens, A; Gaga, M; Greulich, T; Kostikas, K; Lane, S; Marin, JM; Ninane, V; Nunez, X; Patalano, F; Vogelmeier, CF | 1 |
| Barisione, G; Baroffio, M; Brusasco, V | 1 |
| Blais, CM; Cockcroft, DW; Davis, BE | 1 |
| Cazzola, M; Rogliani, P | 1 |
| Buhl, R; Criée, CP; Kardos, P; Lossi, NS; Vogelmeier, CF; Worth, H | 1 |
| Ayers, T; Banerji, D; Ferguson, GT; Fogel, R; Goodin, T; Kerwin, E; Maitra, S; Sanjar, S; Sen, B; Yadao, A | 1 |
| Banerji, D; Fogel, R; Patalano, F | 1 |
| Physicians From Medical Centers In Poland, GO; Płusa, T | 1 |
| Hida, N; Hizawa, N; Nakaizumi, T; Satoh, H; Terashima, H; Yamada, H | 1 |
| Deas, SD; Huprikar, N | 1 |
| Bjermer, L; Costa-Scharplatz, M; Gutzwiller, FS; Keininger, DL; Lisspers, K; Mahon, R; Olsson, P; Roche, N; van Boven, JFM | 1 |
| Cohuet, G; Corradi, M; Fabbri, L; Guasconi, A; Montagna, I; Papi, A; Petruzzelli, S; Prunier, H; Roche, N; Scuri, M; Singh, D; Vestbo, J; Vezzoli, S | 1 |
| Burke, C; Chow, WL; Guruprasad, B; Tee, A | 1 |
| Aalamian-Mattheis, M; Clemens, A; Fogel, R; Kostikas, K; Nunez, X; Pagano, VA; Patalano, F | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Goyal, P; Guerin, T; Hurst, JR; Kostikas, K; Larbig, M; Patalano, F; Pfister, P; Wedzicha, JA | 1 |
| Iwakura, M; Satake, M; Sato, S; Shioya, T; Takahashi, H; Terui, Y; Uemura, S | 1 |
| Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Abu El-Enin, MA; El-Ashry, SM; Hammouda, MEA; Saleh, NM; Salem, YA | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Gutzwiller, FS; Kostikas, K; Larbig, M; Mackay, A; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Ashmawi, S; Backer, A; Diaz, DV; Frith, PA; Gurgun, A; Hamann, AM; Hristoskova, S; Kostikas, K; Krishnamurthy, S; Olsson, P; Pilipovic, V | 1 |
| Kasak, V; Klimes, J; Skoupa, J; Valena, T | 1 |
| Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA | 1 |
| Bentivenga, C; Berardi, E; Borghi, C; Bui, V; Cicero, AF; Cosentino, ER; Esposti, DD; Landolfo, M; Miceli, R; Spinardi, L | 1 |
| Lad, R; Rhee, CK; Yoshisue, H | 1 |
| Dorman, J; Kelly, K; Lacey, S; McGrath, K; Molony, D; O'Doherty, B; Schmid, S; Sullivan, S; Whelan, S | 1 |
| Bowling, A; Goodin, T; Ozol-Godfrey, A; Price, B; Sanjar, S; Sharma, S; Tashkin, DP | 1 |
| Singh, D | 1 |
| Ascuntar, C; Aviles, S; Benavides-Cordoba, V; Mosquera, R; Orozco, L; Rivera, J | 1 |
| Alcazar, B; Barrecheguren, M; Kostikas, K; Mezzi, K; Miravitlles, M; Shen, S; Soler-Cataluña, JJ; Wedzicha, JA | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA | 1 |
| Danyliv, A; Gutzwiller, FS; Lakhotia, B; Mahon, R; Nikolaev, I; Thokala, P | 1 |
| Beier, J; Friedrich, FW; Plate, T | 1 |
| Chapman, KR; D'Andrea, P; Hosoe, M; Kerstjens, HAM; Lavecchia, C; Maspero, J; Pethe, A; Shu, X; Tanase, AM; van Zyl-Smit, RN | 1 |
| Carpaij, OA; Kerstjens, HAM; Niemeijer, A; Seigers, D; van Geffen, WH; Vonk, JM; Westbroek, LF | 1 |
| Abdallah, N; Drollmann, A; Ethell, B; Hahn, M; Heudi, O; Ignatenko, S; Jauernig, J; Last, S; Machineni, S; Radhakrishnan, R; Tillmann, HC; Vaidya, S | 1 |
| Blair, HA | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Bartels, C; Jain, M; Tillmann, HC; Vaidya, S; Yu, J | 1 |
| Aritake, H; Gamo, S; Ichinose, M; Kazama, I; Murakami, K; Nara, M; Sugiura, H; Tamada, T | 1 |
| Elzinga, CRS; Han, B; Maarsingh, H; Meurs, H; Oldenburger, A; Schmidt, M; Sopi, RB; Timens, W; Zuidhof, AB | 1 |
| Bartels, C; Buhl, R; Jain, M; Jauernig, J; Kerstjens, HAM; Nikolaev, I; Tillmann, HC; Vaidya, S | 1 |
| Gallo, O; Mangia, PP; Pradelli, L; Ritrovato, D | 1 |
| Calzetta, L; Facciolo, F; Matera, MG; Nikolaev, I; Ritondo, BL; Rogliani, P | 1 |
| Abo, M; Hara, J; Kasahara, K; Kimura, H; Nishikawa, S; Ogawa, N; Ohkura, N; Sone, T; Tambo, Y; Tanaka, R; Watanabe, S | 1 |
| Kato, C; Nakamura, N; Sasajima, T; Yoshisue, H | 1 |
| Bougard, N; Louis, G; Louis, R; Pétré, B; Schleich, F | 1 |
| de Llano, LP; Domínguez-Ortega, J; Mejía, N; Naval, E | 1 |
| Andaloro, S; Bonavita, O; Crimi, C; Crimi, N; Morini, P; Pelaia, C; Pelaia, G; Ricciardi, L; Rizzi, A; Scichilone, N; Valenti, G | 1 |
| Chan, MC; Chen, NH; Cheng, SL; Hsieh, MJ; Hsu, WH; Kuo, PH; Lin, MS; Liu, CL; Liu, SF; Tao, CW; Tsai, YH; Wei, YF; Wu, YK; Yang, TM | 1 |
26 review(s) available for glycopyrrolate and carbostyril
| Article | Year |
|---|---|
Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Topics: Albuterol; Bayes Theorem; Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome | 2014 |
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Time Factors; Treatment Outcome | 2014 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
[The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Disease Progression; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2014 |
Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Topics: Acetylcholine; Bronchoconstriction; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome | 2015 |
Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2015 |
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Dyspnea; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2015 |
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2015 |
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Topics: Adrenergic alpha-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2015 |
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Topics: Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Dyspnea; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2015 |
Effect of tiotropium on COPD exacerbations: A systematic review.
Topics: Administration, Inhalation; Bronchodilator Agents; Cholinergic Antagonists; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Tiotropium Bromide | 2016 |
[LAMA/LABA fixed dose combination for treatment of COPD].
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Respiratory Function Tests; Tiotropium Bromide; Treatment Outcome | 2016 |
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Drug Combinations; Glucocorticoids; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index | 2017 |
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Bronchodilator Agents; Comparative Effectiveness Research; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Observational Studies as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Approval; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
Topics: Administration, Inhalation; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Tropanes | 2018 |
Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment.
Topics: Adrenergic beta-2 Receptor Agonists; Behavior; Counseling; Delayed-Action Preparations; Drug Therapy, Combination; Energy Metabolism; Exercise; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Self Efficacy; Terbutaline; Treatment Outcome; Tropanes | 2018 |
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Asian People; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Treatment Outcome; Tropanes | 2019 |
Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Quinolones; Receptors, Adrenergic, beta-2 | 2021 |
Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Biological; Mometasone Furoate; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Young Adult | 2021 |
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
Topics: Administration, Inhalation; Asthma; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Quinolones; Treatment Outcome | 2021 |
Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Prospective Studies; Quality of Life; Quinolones; Retrospective Studies | 2022 |
47 trial(s) available for glycopyrrolate and carbostyril
| Article | Year |
|---|---|
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
Topics: Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Combinations; Epidemiologic Methods; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome; Vital Capacity | 2010 |
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Topics: Administration, Inhalation; Aged; Atrial Fibrillation; Blood Pressure; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Female; Glycopyrrolate; Heart Rate; Humans; Hyperkalemia; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Tachycardia, Ventricular | 2010 |
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.
Topics: Administration, Inhalation; Adult; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome | 2013 |
Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Spirometry; Treatment Outcome; Vital Capacity | 2013 |
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
Topics: Adult; Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome | 2014 |
Combined long-acting bronchodilator single therapy for COPD.
Topics: Bronchodilator Agents; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics; Treatment Outcome | 2013 |
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Respiratory System; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Topics: Adult; Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Exercise Tolerance; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung Volume Measurements; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2014 |
Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Blood Glucose; Bronchi; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Glycopyrrolate; Healthy Volunteers; Heart Rate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Potassium; Quinolones; Risk Assessment; Risk Factors; Young Adult | 2014 |
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Area Under Curve; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Inspiratory Capacity; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity | 2014 |
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Single-Blind Method; Translational Research, Biomedical; Treatment Outcome | 2015 |
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Topics: Aged; Albuterol; Androstadienes; Bronchodilator Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Monte Carlo Method; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Sweden | 2014 |
Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2015 |
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
[LAMA/LABA or LABA/ICS?].
Topics: Administration, Inhalation; Drug Therapy, Combination; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Indans; Lung Volume Measurements; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2015 |
[LAMA/LABA supports physical activity in COPD patients].
Topics: Drug Combinations; Glycopyrrolate; Humans; Indans; Motor Activity; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Electrocardiography; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome; United States; Vital Capacity; Vital Signs | 2016 |
[Dual bronchodilators becomes the first choice combination].
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Combinations; Fluticasone; Glycopyrrolate; Guideline Adherence; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Topics: Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Combinations; Exercise; Female; Forced Expiratory Volume; Germany; Glycopyrrolate; Humans; Indans; Inspiratory Capacity; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Efficacy of Double Bronchodilation (LABA+LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer.
Topics: Adenocarcinoma; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Carcinoma, Squamous Cell; Delayed-Action Preparations; Female; Glycopyrrolate; Humans; Indans; Lung Neoplasms; Male; Middle Aged; Muscarinic Antagonists; Pilot Projects; Pneumonectomy; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Tomography, X-Ray Computed | 2016 |
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Diagnosis, Computer-Assisted; Double-Blind Method; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Placebo Effect; Plethysmography, Whole Body; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Sensitivity and Specificity; Spirometry; Switzerland; Treatment Outcome | 2017 |
Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Cholinergic Antagonists; Clinical Protocols; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Republic of Korea; Research Design; Severity of Illness Index; Spirometry; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2017 |
[Study of the month : FLAME study in chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Treatment Outcome | 2016 |
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Sex Factors; Tiotropium Bromide; Vital Capacity | 2017 |
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Disease Progression; Drug Combinations; Drug Substitution; Dyspnea; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Methacholine Chloride; Middle Aged; Muscarinic Antagonists; Quinolones; Saskatchewan; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity; Young Adult | 2017 |
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Topics: Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Severity of Illness Index | 2017 |
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
Topics: Aged; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Economic; Population Surveillance; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden | 2017 |
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Treatment Outcome | 2018 |
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Topics: Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires | 2019 |
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Monitoring; Drug Substitution; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Treatment Outcome | 2018 |
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sex Characteristics; Treatment Outcome | 2019 |
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires | 2020 |
Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Quinuclidines; Treatment Outcome | 2020 |
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Mometasone Furoate; Muscarinic Antagonists; Nebulizers and Vaporizers; Quinolones; Treatment Outcome; Young Adult | 2020 |
Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Ipratropium; Male; Metered Dose Inhalers; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2020 |
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
Topics: Cross-Over Studies; Drug Combinations; Glycopyrrolate; Healthy Volunteers; Humans; Indans; Mometasone Furoate; Quinolones | 2020 |
53 other study(ies) available for glycopyrrolate and carbostyril
| Article | Year |
|---|---|
Pipeline for COPD drugs flows with combination candidates.
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
Bronchodilator combinations for COPD: real hopes or a new Pandora's box?
Topics: Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Quinolones | 2013 |
Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics | 2013 |
COPD treatment: time to change our algorithm?
Topics: Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
2013 American Thoracic Society International Conference.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Analgesics, Non-Narcotic; Asthma; Benzamides; Clofazimine; Congresses as Topic; Cyclobutanes; Drug Combinations; Glycopyrrolate; Hospital Mortality; Humans; Indans; Intensive Care Units; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Societies, Medical; Thoracic Diseases; Treatment Outcome; Tuberculosis, Multidrug-Resistant; United States | 2013 |
QVA149 versus glycopyrronium for COPD.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives | 2013 |
QVA149 versus glycopyrronium for COPD - authors' reply.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives | 2013 |
Lack of clinically relevant differences between combination therapy and monotherapy in COPD.
Topics: Bronchodilator Agents; Female; Glycopyrrolate; Humans; Indans; Male; Quinolones | 2014 |
Lack of clinically relevant differences between combination therapy and monotherapy in COPD.
Topics: Bronchodilator Agents; Female; Glycopyrrolate; Humans; Indans; Male; Quinolones | 2014 |
Indacaterol for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2015 |
In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aerosols; Biological Availability; Bronchodilator Agents; Chemistry, Pharmaceutical; Drug Carriers; Drug Combinations; Drug Delivery Systems; Dry Powder Inhalers; Equipment Design; Glycopyrrolate; Humans; Indans; Lactose; Models, Anatomic; Models, Biological; Muscarinic Antagonists; Particle Size; Pharynx; Powders; Quinolones; Therapeutic Equivalency; Tissue Distribution | 2015 |
Cardiovascular safety of two bronchodilators' fixed-dose combination: indacaterol and glycopyrronium.
Topics: Adjuvants, Anesthesia; Administration, Inhalation; Bronchodilator Agents; Cardiovascular System; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
[Better lung function thanks to fixed combination].
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Quality of Life; Quinolones; Randomized Controlled Trials as Topic | 2015 |
Low Doses of Long-Acting β-Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Simultaneous spectrophotometric determination of indacaterol and glycopyrronium in a newly approved pharmaceutical formulation using different signal processing techniques of ratio spectra.
Topics: Adrenergic beta-2 Receptor Agonists; Capsules; Fourier Analysis; Glycopyrrolate; Indans; Limit of Detection; Muscarinic Antagonists; Quinolones; Spectrophotometry | 2016 |
[Good bronchial dilatation helps keep patients physically active].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Motor Activity; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Seebri Neohaler and Utibron Neohaler for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Glycopyrrolate; Humans; Indans; Lung; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Pregnancy; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Treatment Outcome | 2016 |
Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Biological; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
[Narrowing indications for inhaled steroids in COPD].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
[UBC internal medicine returns to the respiratory tract area].
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Another Choice for Prevention of COPD Exacerbations.
Topics: Adrenergic beta-2 Receptor Agonists; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Topics: Acetylcholine; Adenylyl Cyclases; Adrenergic beta-2 Receptor Agonists; Aged; Bronchi; Bronchoconstriction; Bronchodilator Agents; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; Female; Glycopyrrolate; Humans; In Vitro Techniques; Indans; Male; Middle Aged; Muscarinic Antagonists; Primary Cell Culture; Quinolones; Time Factors | 2016 |
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstruct
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Canada; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluticasone; France; Glycopyrrolate; Health Care Costs; Humans; Indans; Italy; Male; Portugal; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Topics: Adrenergic beta-2 Receptor Antagonists; Aged; Carbachol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Mitogen-Activated Protein Kinase 7; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Quinolones; Signal Transduction; Treatment Outcome | 2017 |
Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.
Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Cattle; Cholinergic Fibers; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Glycopyrrolate; In Vitro Techniques; Indans; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Quinolones; Synaptic Transmission; Trachea | 2017 |
GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Critical Pathways; Disease Management; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Germany; Glycopyrrolate; Humans; Indans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2017 |
[Evaluation of effect of indacaterol (Onbrez) and/or glycopyrronium (Seebri) treatment on Quality of Life of COPD patients in medical practice in Poland - observational study (OSQO)].
Topics: Aged; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Poland; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2017 |
Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzoxazines; Delayed-Action Preparations; Drug Combinations; Dry Powder Inhalers; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Vital Capacity | 2018 |
Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.
Topics: Aged; Bronchodilator Agents; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Hospitals; Humans; Indans; Male; Middle Aged; Probability; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones; Singapore | 2018 |
Validated ion pair chromatographic method for simultaneous determination and in vitro dissolution studies of indacaterol and glycopyrronium from inhaled capsule dosage form.
Topics: Administration, Inhalation; Capsules; Chromatography, Liquid; Glycopyrrolate; Indans; Limit of Detection; Linear Models; Models, Chemical; Quinolones; Reproducibility of Results | 2018 |
Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Czech Republic; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones | 2018 |
Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Comorbidity; Drug Combinations; Female; Glycopyrrolate; Heart Failure; Heart Ventricles; Humans; Indans; Italy; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Readmission; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Health Status; Humans; Indans; Ireland; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Safety; Smoking; Treatment Outcome | 2019 |
One bronchodilator or two? Translating clinical trials into clinical practice.
Topics: Bronchodilator Agents; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide | 2020 |
Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide | 2020 |
COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population.
Topics: Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2020 |
Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Markov Chains; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden; Treatment Outcome | 2020 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.
Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Animals; Bicarbonates; Bronchodilator Agents; Cell Line, Tumor; Cells, Cultured; Cystic Fibrosis Transmembrane Conductance Regulator; Glycopyrrolate; Humans; Hydrogen-Ion Concentration; Indans; Lipopolysaccharides; Mucins; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Mucosa; Swine; Trachea | 2021 |
Effects of (a Combination of) the Beta
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Bronchoconstriction; Bronchodilator Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glycopyrrolate; Guinea Pigs; Humans; Indans; Lung; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Receptor, Muscarinic M3; Receptors, Adrenergic, beta-2 | 2021 |
Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Ag
Topics: Acetates; Adrenal Cortex Hormones; Adult; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2021 |
Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
Topics: Acetylcholine; Anti-Inflammatory Agents; Bronchi; Bronchodilator Agents; Cyclic AMP; Cytokines; Drug Interactions; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Isometric Contraction; Mometasone Furoate; Quinolones; Respiratory Hypersensitivity | 2021 |
Two cases of chronic obstructive pulmonary disease evaluated by dynamic-ventilatory digital radiography for pulmonary function and assessment of treatment efficacy.
Topics: Aged; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Radiographic Image Enhancement; Radiography, Thoracic; Spirometry; Tiotropium Bromide; Treatment Outcome | 2021 |
Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Muscarinic Antagonists; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2022 |
[Fixed combination of mometasone, indacaterol, glycopyrronium for the treatment of severe asthma : Enerzair® Breezhaler®].
Topics: Administration, Inhalation; Asthma; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Pulmonary Disease, Chronic Obstructive; Quinolones | 2021 |
Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Asthma; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Muscarinic Antagonists; Quinolones | 2022 |
Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Retrospective Studies; Taiwan; Tiotropium Bromide; Treatment Outcome | 2022 |